Cocrystal Pharma (COCP)

Executive Summary

Cocrystal Pharma is a clinical-stage biotechnology company leveraging a structure-based drug discovery platform to develop novel antiviral therapeutics. The company's pipeline includes CC-42344 for influenza A (Phase 1 completed), CDI-31244 for hepatitis C (Phase 2 completed), and CDI-988 for norovirus (currently in a Phase 1/2 trial). With a focus on broad-spectrum and resistance-resistant antivirals, Cocrystal aims to address significant unmet medical needs. The recent initiation of a Phase 1/2 trial for CDI-988 in norovirus represents a key near-term value driver.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 norovirus trial interim data for CDI-98830% success
• H1 2027Initiation of Phase 2 trial for CC-42344 in influenza A40% success
• TBDPotential partnership or licensing deal for hepatitis C or influenza program20% success